Clinical trials: Viral Hepatitis C
Chronic Hepatitis C, Renal Impairment
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
Grazoprevir (MK-5172) and Elbasvir (MK-8742) were studied as the principal components of combination oral therapy for hepatitis C virus (HCV).
- Trial name
- NCT01937975
- Testing
- Grazoprevir, Elbasvir
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HCV Infection
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection
This a phase 2, randomized, open-label trial of GS-9256 plus GS-9190, two oral anti HCV drugs, for 28 days with and without ribavirin (RIBA) and with pegylated interferon (PEG)/RIBA in adults with chronic Hepatitis C virus (HCV).
- Trial name
- NCT01072695
- Testing
- GS-9256, GS-9190, Ribavirin
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 46 people
- Sponsor
- Gilead Sciences
Hepatitis C
Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
This is a multi-site, open-label trial evaluating the safety and efficacy of 100 mg of grazoprevir (MK-5172) used in combination with or without 50 mg of elbasvir (MK-8742) and/or ribavirin (RBV) in treating non-cirrhotic…
- Trial name
- NCT01932762
- Testing
- Grazoprevir, Elbasvir, Ribavirin
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)
The purpose of this study is to assess the efficacy and safety of grazoprevir (MK-5172) 100 mg in combination with elbasvir (MK-8742) 50 mg in the treatment of chronic hepatitis C virus (HCV) in participants who are co-infected…
- Trial name
- NCT02105662
- Testing
- Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets
- Volunteers
- 218 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment
The purpose of this study is to assess the effect of renal function impairment on the single dose pharmacokinetics of Daclatasvir.
- Trial name
- NCT01830205
- Testing
- Daclatasvir
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic, Hepacivirus
Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)
In this study, adult Indonesian subjects with human immunodeficiency virus (HIV) coinfected with chronic hepatitis C (CHC) will be given peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) combination therapy.
- Conditions
- Hepatitis C, Chronic, Hepacivirus, HIV Infections
- Trial name
- NCT00687544
- Testing
- Peginterferon alfa-2b (SCH 054031), Ribavirin (SCH 018908)
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients
A Phase II, Open Label, Multi-Center, Proof-Of-Concept Study determing whether treatment with HDV-Interferon (HDV-IFN), by oral or subcutaneous (injection) routes, and ribavirin results in similar efficacy [Rapid Virologic…
- Trial name
- NCT00703872
- Testing
- Oral HDV-Interferon + ribavarin, Injectable HDV-Interferon + ribavarin
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Hepasome Pharmaceuticals
Chronic Hepatitis C
Trial of Pegasys® in Patients With Chronic Hepatitis C
The purpose of this study is to investigate the efficacy and safety of Pegasys® 180μg for subcutaneous (s.c.) injection in interferon (IFN)-treated or IFN-untreated chronic hepatitis C patients except for those infected with…
- Trial name
- NCT00245414
- Testing
- Pegasys®
- Where
- 6 sites in Japan
- Volunteers
- 108 people
- Sponsor
- Chugai Pharmaceutical
Chronic Hepatitis C, Cirrhosis
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
The purpose of this study is to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in US veterans with genotype 1 chronic hepatitis C virus infection.
- Conditions
- Chronic Hepatitis C, Cirrhosis, Hepatitis C Virus
- Trial name
- NCT02442284
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, Ribavirin
- Volunteers
- 99 people
- Sponsor
- AbbVie
Hepatitis C Virus
TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435
The purpose of the study is to investigate the effect of moderate and severe hepatic impairment on the pharmacokinetics of TMC435.
- Trial name
- NCT01046058
- Testing
- TMC435
- Where
- 3 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C
Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
To study the combination of Daclatasvir and Sofosbuvir for the treatment of hepatitis C virus (HCV) Genotype 3 infection
- Trial name
- ALLY 3 (NCT02032901)
- Testing
- Daclatasvir, Sofosbuvir
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 173 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C
This multicenter, observational study will assess the efficacy and the safety of Pegasys (peginterferon alfa 2a) in dual- or triple therapy in patients with chronic hepatitis C.
- Trial name
- NCT01679834
- Where
- 2 sites in Germany
- Volunteers
- 7,500 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing
The purpose of this study is to examine the safety, tolerability and pharmacokinetics of increasing oral doses of TMC435350 after single and repeated dosing, followed by an open label repeated dosing session in 6 HCV genotype1…
- Trial name
- NCT00938899
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis
Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU)
The study aims to collect information on the current treatment patterns for Hepatitis C in participating countries. There is also a focus on patients receiving a daclatasvir-containing treatment regimen who will be followed…
- Trial name
- NCT02368522
- Where
- Germany
- Volunteers
- 920 people
- Sponsor
- Bristol-Myers Squibb
Liver Fibrosis, Hepatitis C Virus
Magnetic Resonance Elastography for Assessment of Liver Fibrosis (MK-0000-132)(COMPLETED)
This study will assess the repeatability of Magnetic Resonance Elastography (MRE) in both healthy volunteers and Hepatitis C Virus (HCV)-infected patients with fibrosis and lay the groundwork for the validation of MRE as an…
- Trial name
- NCT00896233
- Testing
- MRE
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)
This is a two-part study of grazoprevir (MK-5172) + elbasvir (MK-8742) in Japanese participants with chronic hepatitis C virus (HCV) genotype 1 (GT1).
- Trial name
- NCT02203149
- Testing
- Grazoprevir, Elbasvir
- Volunteers
- 399 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects
The primary purpose of this study is to assess the change in HCV RNA during dosing with BMS-650032 and during the follow-up period in subjects with chronic hepatitis C infection
- Trial name
- NCT00722358
- Testing
- BMS-650032
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus
Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
This study is to to evaluate the safety, tolerability, and efficacy of sofosbuvir (SOF) plus ribavirin (RBV) in Egyptian adults with genotype 4 hepatitis C virus (HCV) infection.
- Trial name
- NCT01838590
- Testing
- SOF, RBV
- Where
- 2 sites in Egypt
- Volunteers
- 103 people
- Sponsor
- Gilead Sciences
HIV Infections, Hepatitis C
Multicenter Performance Study of QuadQuik Invitro Diagnostic Device
To Demonstrate Clinical Performance of the TriQuik Invitro Diagnostic Device
- Conditions
- HIV Infections, Hepatitis C, Hepatitis B, Syphilis Infection
- Trial name
- NCT05692505
- Testing
- QuadQuik
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Genlantis Diagnostics
Chronic Genotype 1 Hepatitis C Virus Infection
A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.
- Trial name
- NCT01247194
- Testing
- PPI-461
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 24 people
- Sponsor
- Presidio Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.